Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV
Status:
Completed
Trial end date:
2018-03-27
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability
of treatment with sofosbuvir (SOF)/velpatasvir (VEL; GS-5816) fixed-dose combination (FDC)
for 12 weeks in participants with chronic hepatitis C virus (HCV) infection.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Sofosbuvir Sofosbuvir-velpatasvir drug combination Velpatasvir